NICE issued draft recommendations, stating that sorafenib is not...

NICE issued draft recommendations, stating that sorafenib is not cost-effective to treat advanced hepatocellular carcinoma in adults when surgical or loco regional therapies have failed. The full document can be viewed on: https://www.nice.org.uk/guidance/GID-TA10055/documents/appraisal-consultation-document

This is the second time that NICE has reviewed sorafenib. In 2010 it was deemed not cost-effective and thus not funded by the NHS, but was subsequently funded through the Cancer Drugs Fund (CDF). This review has come around because NICE is now responsible for the CDF and are looking to review the existing treatments for continued inclusion on the CDF.

What impact does this decision have on clinical studies using Sorafenib as a comparator? Comparator now is palliative care.

Has this decision opened or closed the door for Y-90 ?